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tumour type, treatment methods used. Clinically signiﬁcant symptoms 
are found in 20-60% cancer patients. Lung cancer anaemia, deﬁnited as 
haemoglobin level below 12 g/dl is seen in 25-60% of patients depend-
ing on clinical stage (I-IV).
Materials and Methods: Between August 1997 and July 2000 in 
The Maria Sklodowska-Curie Memorial Cancer Centre and Institute, 
Department of Lung Cancer and Thoracic Tumours, 112 patients were 
treated by chemoradiotherapy with stage IIIA and IIIB non-small lung 
cancer. Thirty eight of patients were analyzed (31 males and 7 females). 
Median age was 57.8 (range 38-72). Current and never smokers consti-
tuted respectively 71% and 29% of patients.
Karnofsky status performance deﬁned as 100, 90, 80 was found in re-
spectively 36.8%, 47.4% and 15.8% of patients. Clinical stage IIIA and 
IIIB were diagnosed in 14 (36.8%) and 24 (63.2%) patients. Sequential 
treatment was given to 24 (63.2%) and concurrent chemoradiation 
was used in 14 (36.8%) patients. All patients received cisplatin and 
vinorelbine. All patients were irradiated to 60 Gy, using 3D planning 
system (Helax).
Results: Thirty six patients (94.7%) received planned treatment (2 
cycles of chemotherapy and irradiation). Only two patients (5.3%) 
had not completed treatment. Seventy eight chemotherapy cycles was 
given. Cisplatin total dose was between 130 to 360 mg per patient 
(median: 271 mg). Median treatment time was 46.1 days (range: 10-74 
days). Overall survival time in all patients was 98.3 weeks (range: 23-
389 weeks). Median time to progression was 34.6 weeks (range: 1-130 
weeks). Median haemoglobin serum level before treatment was 12.7 
g/dl (range: 10.2-16.0 g/dl). Median haemoglobin serum level after 
treatment was 12.4 g/dl (range: 7.7-16.1 g/dl). Median haemoglobin 
serum level one month after the end of treatment was 12.8 g/dl (range: 
8.1-15.3 g/dl).
Summary: Anaemia could be found as independent prognostic factor 
for overall survival time of lung cancer patients treated by combined 
radiochemotheraphy and it also may offer a predictive value. The corre-
lation between serum haemoglobin level and survival will be presented.
Table. Clinical Characteristics
Parameter Pts %
Female 7 18.4
Male 31 81.6
Smokers 27 71
Never smokers 11 29
KPS 100 14 36.8
KPS 90 18 47.4
KPS 80 6 15.8
T2 8 21.1
T3 13 34.2
T4 17 44.7
N0 2 5.3
N1 1 2.6
N2 31 81.6
N3 4 10.5
CS IIIA 14 36.8
CS IIIB 24 63.2
RTCT concurrent 14 36.8
RTCT sequential 24 63.2
SCC 28 73.4
AC 1 2.6
NSCLC no subtype 9 23.7
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Background: NVB i.v. with CDDP has reported an optimal activity/
tolerance ratio when used in combination with radiotherapy (RT). The 
new oral formulation of NVB should be easier to use assuming a simi-
lar activity proﬁle. An international phase II trial with NVBo + CDDP 
as induction, followed by NVBo + CDDP + RT was implemented in 
order to evaluate the objective response (OR) following this combina-
tion by SWOG modiﬁed criteria and its safety (NCI-CTC v2).
Material and Methods: Patients (pts) between 18 and 70 years, with 
histologically proven untreated locally advanced inoperable stage 
IIIA/IIIB (supraclavicular lymph nodes and pleural effusion excluded) 
NSCLC, adequate bone marrow, hepatic and renal function, KPS ≥ 
80%, were treated with NVBo D1,8 60 mg/m2 cycle 1 and 80 mg/m2 
cycle 2 (if no grade 3-4 toxicity) and CDDP 80 mg/m2 every 3 weeks 
for 2 cycles as induction. Patients without progression received NVBo 
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D1,8 40 mg/m2 and CDDP 80 mg/m2 every 3 weeks for 2 more cycles 
and RT 66 Gy in 6.5 weeks. 
Results: Between 12/01 and 12/03, 54 pts were enrolled; stages IIIA 
48%, IIIB 52%; squamous 59%; median age 57 years (range 41-71), 
median KPS 100% (range 80-100%), 7% pts ≥ 5% weight loss at 
baseline. Relative dose intensities of NVBo/CDDP were 86%/93% and 
97%/98% at induction and in combination with RT, respectively. Forty-
one pts (76%) during induction increased NVBo from 60 to 80 mg/m2. 
Reasons for non-escalation: haematological 7 pts, non-haematological 
2, mistake 4. After 2 cycles of CT induction, OR (ITT) in the 54 pts 
was 37%. Toxicity during induction: G3-4 neutropenia (28%), febrile 
neutropenia (7%), G3 nausea (11%), G3-4 vomiting (9%), G3 anorexia 
(4%), G4 diarrhoea (2%), G3 constipation (2%). Forty-seven out of 
54 pts received CT-RT. Median RT delivered dose: 66 Gy. Tolerance: 
9% G3 neutropenia; no G3/4 oesophagitis; 2% G3 radiation dermatitis. 
Late pulmonary ﬁbrosis 1 pt. One month after CT-RT completion, OR 
(ITT) in the 54 pts was 54% (95%CI: 40%;67%). Median PFS/OS: 
12.5 (95%CI: 9.6;16.4) /23.4 (95%CI: 17.6;29.8) months, respectively.
Conclusion: NVB Oral with CDDP is effective in stage IIIA/IIIB pts. 
The excellent tolerance proﬁle allowed to complete the CT-RT treat-
ment in 94% of pts. NVB oral is a new and promising option which 
facilitates the concomitant administration of CT-RT.
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Background: SWOG 9504 demonstrated the beneﬁt of D consolida-
tion after E + C with radiation therapy in pts with locally advanced 
NSCLC. This study was developed to assess the feasibility and efﬁcacy 
of consolidation with either G alone or with D after the same chemora-
diation schedule as SWOG 9504.
Methods: The treatment schema included concurrent C 50 mg/m2 Day 
1, 8 + E 50 mg/m2 Day 1-5 for two 28-day cycles + RT 61-62 Gy over 
7 weeks, after which pts were randomized to consolidation treatment of 
either G 1000 mg/m2 Day 1, 8 (Arm A) or G 1000 mg/m2 Day 1, 8 + D 
75 mg/m2 Day 1 (Arm B) every 21 days for 3 cycles. Eighty-three pts 
were registered, and 58 were randomized to consolidation.
Results:
Characteristics/Results Induction Arm A Arm B
No. of available pts 83 32 32
Median age, yrs 59.0 59.5 59.5
Male 58 26 26
ECOG PS 0 32 11 13
ECOG PS 1 48 20 18
No. of pts assessed for safety, 
Consolidation  23 28
Neutropenia, Grade3/4, %  17.4 42.9
Febrile neutropenia, Grade 3/4, %  0 7.1
Thrombocytopenia, Grade 3/4, %  0 17.9
Anemia, Grade 3/4, %  0 7.1
Dyspnea, Grade 3/4, %  0 7.1
Pneumonitis, Grade 3/4, %  4.3 0
Fatigue, Grade3/4, %  4.3 17.9
Alopecia, Grade 2, %  4.3 3.6
Esophagitis, Grade 3/4, %  0 0
No. of cycles administered, %    
One  8.7 14.3
Two  4.3 25.0
Three  87.0 60.7
Response to chemoradiation    
No. assessed 83 29 29
CR, %  0 0
PR, % 44.6 55.2 62.1
SD, % 21.7 37.9 20.7
PD, % 3.6 0 0
Unknown, % 30.1 6.9 17.2
No. events for PFS  17 9
Median PFS, months  7.1 m 14.6 m
(95% CI)  (5.1, 10.7) (6.1, 24.3)
N for survival  32 32
Median follow-up for survival, 
months  15.5 m 11.2 m
No. events for survival  10 6
Median survival, months  18.5 NE
(95% CI)  (8.9, NE) (19.6, NE)
 
Conclusions: G or G+D following chemoradiation in locally advanced 
NSCLC is well tolerated. Preliminary data indicate that consolida-
tion with G+D resulted in a greater response rate and longer PFS. The 
doublet, as expected, resulted in more toxicity, particularly myelosup-
pression and fatigue.
